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Aims A reduction in the level of thioredoxin 1 (Trx1) has been proposed as a possible mechanism for the tumor-speciﬁc
growth arrest caused by inhibition of histone deacetylases (HDACs). In this study, we investigated the effect of tri-
chostatin A (TSA), a potent HDAC inhibitor, on the proliferation and migration of vascular smooth muscle cells
(VSMCs), and we examined the role of reduced Trx1 levels in this effect.
Methods
and results
TSA treatment time-dependently decreased Trx1 expression in rat VSMCs at both the mRNA and protein levels. It
also enhanced platelet-derived growth factor (PDGF)-induced proliferation and migration of the VSMCs. By poten-
tiating Akt phosphorylation, the siRNA-induced downregulation of Trx1 also enhanced VSMC proliferation and
migration in response to PDGF or serum treatment. Consistent with these results, TSA administration increased
neointimal thickening in a murine model of post-angioplastic restenosis.
Conclusion These data demonstrate that TSA enhances vascular proliferative activity by downregulating Trx1, thus activating an
Akt-dependent pathway. Our results indicate that, in addition to its apoptotic effects in tumour cells, the down-
regulation of Trx1 has a proliferative role in primary VSMCs.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Superoxide anions, hydrogen peroxide, and other reactive oxygen
species(ROS)aregeneratedinsidecellsinresponsetophysiological
stimulation by growth factors or cytokines. ROS affect signal trans-
ductionpathwaysbydirectlyorindirectlymodifyingsignalmolecules
such as protein kinases, transcription factors, phospholipases, phos-
phatases, ion channels, and G proteins.
1 Dysregulated ROS gener-
ation has been implicated in the pathophysiology of various human
diseases, including cancer and cardiovascular disease.
1
By modulating gene expression, the regulation of histone acety-
lation by histone acetyl transferase and histone deacetylase
(HDAC) plays an important role in cell growth and differentiation.
Preclinical studies have demonstrated that HDAC inhibitors, such
as trichostatin A (TSA), suberoylanilide hydroxamic acid, and
NSC3852,
2 exert signiﬁcant anti-proliferative effects on various
cancers by inducing apoptosis, growth arrest, and differen-
tiation.
3–6A reduced level of thioredoxin 1 (Trx1) leading to gen-
eration of ROS and ultimately to mitochondrial dysfunction is
alleged to be responsible for the HDAC inhibitor-mediated cyto-
toxicity observed in transformed tumour cells.
2,7
By acting as a hydrogen donor for many protein targets and sca-
vengers of ROS, such as peroxiredoxin (Prx), Trx plays a key role
in the redox regulation of signal transduction. Physiologically, Trx is
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doi:10.1093/cvr/cvp263thought to exert a cytoprotective effect against oxidative stress by
scavenging ROS, either by itself or in conjunction with Prx.
8 The
exact function of Trx1 in normal tissues remains unclear,
however; Trx1-deﬁcient embryos exhibit early lethality, suggesting
that Trx1 is essential for normal development.
9
Theabnormalproliferationandmigrationseeninvascularsmooth
muscle cells (VSMCs) are major pathophysiological processes seen
in various cardiovascular diseases, including atherosclerosis, post-
angioplastic vascular remodelling, and transplant vasculopathy.
10
Accordingly, the aim of this study was to examine the therapeutic
potential of TSA as an anti-proliferative drug for vascular disease.
Unexpectedly,wefoundthatTSAhasaparadoxicalpro-atherogenic
effect on VSMCs via the reduction of Trx1.
2. Methods
2.1 Cell culture
Primary cultures of rat aortic smooth muscle cells were prepared from
the thoracic and abdominal aortas of 5-week-old male Sprague-Dawley
rats (150–200 g). Cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and were used between passages 5 and 10. For the experiments,
a conﬂuent monolayer of primary cultured VSMCs was subcultured
every 5–7 days (1:5 ratio) up to 10 passages. For the standard exper-
iments, primary VSMCs were maintained at 80% of conﬂuence. The
purity of the cultures was analysed using FACStar (Becton Dickinson,
Mountain View, CA, USA) after staining with ﬂuorescein isothiocya-
nate (FITC)-conjugated antibody against a-smooth muscle actin
(SMA). Cells were used for experiments when more than 97% of
the cells were positive for SMA.
2.2 Reagents
Trichostatin A and platelet-derived growth factor (PDGF)-BB were
obtained from Sigma-Aldrich (St Louis, MO, USA). LY294001 and
U0126 were purchased from Calbiochem (La Jolla, CA, USA). HeLa
cells were grown in DMEM supplemented with 10% FBS.
3-(4,5-Dimethylthiaziazol-2-yl)2,5-diphenyl tetrazolium bromide
(MTT) and dimethylsulfoxide (DMSO) were purchased from
Sigma-Aldrich. 2’,7’-dichloroﬂuorescein diacetate (H2DCF-DA) and
TRIzol reagent were from Invitrogen (Carlsbad, CA, USA). Antibodies
against Trx1, Trx2, Prx1, and Prx2 (Ab Frontier, Suwon, Korea) were
used to detect antioxidants. Antibodies against p-Akt, Akt, p-ERK, ERK,
and b-actin were obtained from Cell Signaling Technology (Beverly,
MA, USA). LipofectAMINE (Invitrogen) was used for the knockdown
experiment, and small interfering RNA (siRNA) against rat Trx 1 and
Prx 2 was obtained (Bioneer, Daejeon, Korea), and a scramble
siRNA was used as a control.
2.3 MTT assay
Cell growth and viability were analysed using the MTT method. Brieﬂy,
cells were incubated with 0.5 g/L MTT for 2 h. After the formation of
formazan crystals, the culture supernatant was removed, and the for-
mazan crystals were dissolved in DMSO. The absorbance of the sol-
ution at 570 nm was measured using a microplate reader (Bio-Rad,
Richmond, CA, USA).
2.4 Measurement of intracellular ROS levels
To analyse intracellular ROS levels, the oxidation-sensitive ﬂuor-
escence probe H2DCF-DA was used as previously described.
11
H2DCF-DA was pre-diluted to a ﬁnal concentration of 2.5 mmol/L.
Cellular ﬂuorescence was measured using an inverted epiﬂuorescence
microscope (Zeiss, Go ¨ttingen, Germany).
2.5 Western blot analysis
Soluble cell extracts were prepared, and aliquots containing 20 mgo f
total protein were separated on 12 or 13.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS–PAGE) gels and transferred
to nitrocellulose membranes. The membranes were probed with
speciﬁc antibodies against the corresponding proteins.
2.6 Reverse transcriptase–polymerase
chain reaction
Total RNA was extracted using TRIzol reagent. First-strand cDNA was
synthesized from 1 mg of total RNA under RNase-free conditions and
ampliﬁed by PCR using primers for human and rat Trx1, rat Prx 2, and
various components of NADPH oxidase complexes. The primers used
for PCR are given in Table 1. PCR reactions were performed using an
initial denaturation step at 958C (5 min) followed by 20–25 cycles of
948C (20 s), 608C (30 s), and 728C (30 s).
2.7 Transfection of small interfering RNA
Cells were transfected with small interfering RNA (siRNA) using
LipofectAMINE 2000 according to the manufacturer’s protocol. The
siRNAs targeting human and rat Trx1 were generated based on
nucleotides 246–264 and 268–286, respectively, of the Trx1
cDNAs from these organisms and were each used at 40 nmol/L. The
siRNAs targeting rat Prx2 were generated based on nucleotides
789–807 of the Prx2 cDNAs. A scrambled siRNA was used as a nega-
tive control.
2.8 Wound-healing assay
Adherent cells (2   10
5) were scraped off the bottom of a culture
plate using a pipette tip to create a cell-free (wounded) area. The
cell culture was washed with phosphate-buffered saline to remove
cell debris and then incubated with PDGF for 48 h. Migration distance
was determined using i-Solution (iMTechnology, Korea), and the short-
est distance between cells that had moved into the wounded region
and their respective starting points was determined.
2.9 Murine carotid ligation model
The carotid artery ligation model was described previously.
12 Male
C57/BL6 mice (20–25 g) were used for all experiments and were
handled in compliance with the Guide for the Care and Use of Labora-
tory Animals of Ewha Women’s University, Seoul, Korea. Mouse
carotid artery remodelling was induced through ligation of the left
common carotid proximal to its bifurcation. The investigation con-
forms to the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
2.10 Statistical analysis
Data are presented as the mean+signiﬁcant deviation (SD). Levels of
signiﬁcance for comparisons between two independent samples were
determined using the Student’s t-test. Groups were compared using
ANOVA with Tukey’s ‘honestly signiﬁcant difference’ post hoc test
applied to signiﬁcant main effects (SPSS 12.0K for Windows, SPSS,
Chicago, IL, USA).
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3.1 TSA potentiates vascular
proliferation in vitro and in vivo
To test the effect of TSA on vascular proliferation in vivo, we used a
mouse carotid ligation model. Two weeks after ligation, quantitat-
ive analysis demonstrated that the neointimal area was 2.5 times
larger in TSA-treated animals than in control animals (0.020+
0.014 vs. 0.050+0.052 mm
2; P ¼ 0.007, Student t-test)
(Figure 1). The neointimal/medial area ratio was as much as 2.2
times larger in TSA-treated animals than in non-treated animals
(2.01+1.67 vs. 0.57+0.45, P ¼ 0.013). Contrary to our initial
expectation that an HDAC inhibitor might have an anti-
proliferative effect, these results clearly indicate that TSA enhances
VSMC proliferation after carotid ligation injury in vivo.
We also examined whether TSA exposure affected the prolifer-
ation of VSMCs in vitro. To this end, VSMCs were exposed to TSA
before stimulating growth with PDGF. As expected, the growth
rate of VSMCs treated with 1 mg/L PDGF for 24 h was up to
three times greater than that of the untreated control VSMCs.
This stimulatory effect of PDGF on VSMC growth was signiﬁcantly
increased by a 48 h pre-treatment of the cells with TSA (Figure 2A),
indicating that exposure to TSA signiﬁcantly increases VSMC
proliferation.
Next, we analysed the effect of TSA on PDGF-induced
migration, another important phenotype of VSMCs, using a
wound-healing assay. TSA had a minimal effect on the total
number of cells induced to migrate by PDGF, but it did increase
the proportion of cells that migrated farther: the proportion that
moved more than 150 mm was higher than in the group treated
with PDGF alone (Figure 2B). These results clearly indicate that
the PDGF-induced growth and migration of VSMCs are augmented
by TSA in vitro and in vivo.
3.2 TSA increases the level of
intracellular ROS by downregulating
Trx1 expression
In transformed tumour cells, HDAC inhibitors have been associ-
ated with increased intracellular oxidative stress resulting from
the transcriptional perturbation of antioxidant proteins.
13 There-
fore, we examined the effect of TSA on intracellular ROS levels
in VSMCs. We found that exposure of VSMCs to TSA led to a
signiﬁcant increase in the level of intracellular ROS (Figure 3A).
When we subsequently examined whether TSA exposure affected
the expression of antioxidant proteins in VSMCs, we found that
TSA exposure led to a signiﬁcant decrease in the level of Trx1
in a time-dependent manner; whereas the expression of Trx 2,
another isotype of Trx was unaffected by the same treatment
(Figure 3B). The expression of Prx1 and Prx 2 was also suppressed
by TSA treatment. RT–PCR analysis showed that TSA treatment
decreased the levels of Trx1 and Prx2 mRNA (Figure 3C).
Figure 1 Prior exposure to an HDAC inhibitor potentiates
neointima formation in balloon-injured arteries. Animals were
injected with either vehicle (10 mL/kg, 2% DMSO in saline)
(n ¼ 8) or TSA (1 mg/kg; at 10 mL/kg, 2% DMSO in saline)
(n ¼ 7) intraperitoneally at the time of ligation injury, 1 day
before injury, and 6 days after injury. The quantiﬁcation of
neointimal thickening was performed 2 weeks after ligation
using the computer program i-Solution. Scale bar ¼ 100 mm.
...............................................................................................................................................................................
Table 1 Nucleotide sequences of primer used for RT–PCR
Forward (50–30) Reverse (30–50)
Trx 1 TCAGGAGGCCCTGGCCGCTG TAGCACCAGAGAACTCCCCAACC
Prx 2 CCGAAAGCTAGGCTGCGAGG AAGGCCTGGACGAGGCGGAG
NOX 1 GTGGCTTTGGTTCTCATGGT TGAGGACTCCTGCAACTCCT
NOX 2 ACCCTTTCACCCTGACCTCT TCCCAGCTCCCACTAACATC
NOX 4 GGGCCTAGGATTGTGTTTGA CTGAGAAGTTCAGGGCGTTC
p22 phox TTGTTGCAGGAGTGCTCATC CTGCCAGCAGGTAGATCACA
b-Actin ATGCCCCGAGGCTCTCTTCC TAGGAGCCAGGGCAGTAATCT
Role of Trx1 in TSA-mediated vascular proliferation 243These results clearly indicate that TSA treatment reduced the
expression of Trx1 and Prx2, at least at the mRNA level. We
further tested the possibility that the TSA-induced increase in
intracellular ROS is caused by altered expression of NADPH
oxidase complex, which is the major enzyme responsible for intra-
cellular ROS generation in response to various extracellular
stimuli.
14 As expected, TSA treatment had no signiﬁcant effect
on the mRNA expression levels of NADPH oxidase components
including NOX proteins (Figure 3D).
A role for Trx1 downregulation in the observed increase in ROS
levels was conﬁrmed using Trx1-speciﬁc siRNA. Downregulation
of the Trx1 protein level by the transfection of Trx1-speciﬁc
siRNA (Figure 4A) signiﬁcantly increased the DCF-DA ﬂuorescence
intensity (Figure 4B), indicating an increase in ROS accumulation.
We observed similar results in HeLa cells (see Supplementary
material online, Figure S1). These results suggest that TSA increases
intracellular ROS levels in VSMCs and HeLa cells by suppressing
the expression of antioxidant proteins such as Trx1 and Prx 2.
To further conﬁrm the involvement of Trx 1 on the expression
of NADPH oxidase components, we examined the effect of Trx 1
knockdown on the serum-induced expression of NADPH oxidase
components. Serum addition suppressed the NOX 4 and p22
phox expression, and this suppressive effect did not differ
between cont siRNA- and Trx 1 siRNA-transfected cells
(Figure 4C). We also showed that the expression and phosphoryl-
ation of p47 phox, the cytosolic component of NADPH oxidase,
were not changed by Trx 1 knockdown (Figure 4D and E). These
results collectively indicate that Trx 1 knockdown does not
affect the activation of membranous and cytosolic NADPH
oxidase components.
3.3 Downregulation of Trx1 increases
proliferation and migration of VSMCs
To further investigate the involvement of Trx 1 in the growth of
VSMCs, we examined the effect of Trx 1 downregulation on the
proliferation of VSMCs. The results demonstrate that
siRNA-induced inhibition of Trx1 expression signiﬁcantly upregu-
lated the growth rate of VSMCs in the presence of PDGF or
serum (Figure 5A and B). This ﬁnding is clearly contradictory to pre-
vious reports that the inhibition of Trx1 by TSA treatment
or siRNA signiﬁcantly suppressed the growth of HeLa cells
(see Supplementary material online, Figure S2).
5,6
Migration in the presence of PDGF or serum was also enhanced
by siRNA-induced inhibition of Trx1 (Figure 5C and D). Pre-
incubation with various ROS scavengers such as N-acetylcysteine
and vitamin E abrogated the enhancing effect of Trx1-speciﬁc
siRNA on growth and migration by VSMCs (data not shown).
These results clearly indicate that PDGF- and serum-induced
growth and migration are enhanced by Trx1 inhibition in an ROS-
dependent manner.
Because we observed reduced Prx2 expression with TSA treat-
ment, we examined the effect of Prx2 inhibition on the growth and
migration of VSMCs further by using Prx2-speciﬁc siRNA. In
common with Trx 1 inhibition, reduced Prx 2 expression increased
the proliferation of VSMCs (Figure 5E), which is consistent with our
previous report that Prx 2 deﬁciency results in increased pro-
duction of ROS and subsequent increased neointimal thickening
in a murine restenosis model.
15 However, Prx 2 knockdown did
not induce any signiﬁcant increase in PDGF- or serum-induced
migration, in contrast to the results of Trx 1 knockdown
(Figure 5F). These results suggest that the enhanced migration of
VSMCs observed in our study was mediated by a decreased inter-
action of Trx1 with target proteins other than Prx 2.
Figure 2 Effect of TSA on PDGF-induced growth and
migration of VSMCs. (A) VSMCs were incubated in the absence
or presence of 0.5 mmol/L TSA for 48 h and then treated with
1 mg/L PDGF for an additional 24 h. Growth rates were
measured using the MTT test. (Tukey post hoc test applied to sig-
niﬁcant group effects in analysis of variance: F3,28 ¼ 205.19,
P , 0.001). (B) VSMCs were incubated in the absence or pres-
ence of TSA for 48 h and scraped with a pipette tip. Cells
were then incubated in the absence or presence of 5 mg/L
PDGF for 48 h. P-values are indicated for statistically signiﬁcant
differences (Student’s t-test). The vertical axis represents the
number of cells that migrated into the wounded region.
Stacked bars display the portion of migratory cells classiﬁed by
migration distance.
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serum-induced phosphorylation of Akt
Pre-treatment with LY294002, a pharmacological inhibitor of Akt,
almost completely abrogated serum-induced proliferation and
migration of VSMCs (Figure 6A and B). Treatment with serum
induced rapid Akt phosphorylation, but this effect was dramatically
suppressed by pre-treatment with various ROS scavengers
(Figure 6C), clearly indicating that signal-dependent production of
intracellular ROS is critical for the serum-dependent activation
of the Akt signalling pathway. In addition, Trx1 inhibition and a
subsequent rise in ROS enhanced the serum-dependent phos-
phorylation of Akt after 15 min of serum reconstitution and
prolonged stimulation with serum (48 h) (Figure 6D).
Collectively, these results suggest that Trx1 inhibition increases
serum-induced growth and migration of VSMCs by enhancing the
activation of Akt, a key signalling protein responsible for cellular
growth and migration.
4. Discussion
In our experiments, TSA treatment of VSMCs inhibited the
expression of Trx1 and induced a subsequent accumulation of
ROS. This TSA-induced downregulation of Trx1 was expected
to inhibit cell growth. However, contrary to our expectations,
Trx1 inhibition and the subsequent increase in intracellular ROS
levels augmented PDGF-induced proliferation and migration in
VSMCs. Although HDAC inhibitors have emerged as potential
anticancer drugs, TSA has been shown to exacerbate neointimal
proliferation in low-density lipoprotein receptor-deﬁcient mice
and to promote hypertrophy of cardiac myocytes in neonatal
rats.
16,17 Inhibition of Trx in the heart has also been reported to
increase oxidative stress and cardiac hypertrophy.
18 To our best
knowledge, our ﬁndings are the ﬁrst to demonstrate that the
downregulation of Trx1 is associated with vascular proliferation
in vitro and in vivo.
Trx serves a key redox function in regulating signal transduction;
reduced Trx catalyses the reduction of disulﬁde bonds in many
proteins, such as PTEN and ASK1.
19,20 Trx-deﬁcient mice are
embryonic lethal, whereas Trx-overexpressing transgenic mice
are more resistant than are control mice to various inﬂammatory
responses.
9,21 Physiologically, Trx is thought to exert a cytoprotec-
tive effect against oxidative stress by scavenging ROS, perhaps in
conjunction with Prx.
8 However, the exact function of Trx1 in
normal tissues remains unclear because of the early lethality of
the Trx1-deﬁcient embryo. Because Trx functions as a hydrogen
donor for many protein targets and scavengers of ROS, such as
Prx, Trx downregulation might be anticipated to lead to ROS
Figure 3 The effect of TSA on antioxidant expression and intracellular ROS levels. (A) VSMCs were incubated in the absence or presence of
0.5 mmol/L TSA for 48 h, and intracellular ROS levels were determined by staining with DCF-DA. P-values are indicated for statistically signiﬁ-
cant differences (Student’s t-test). (B) VSMCs were incubated with TSA for various lengths of time, and soluble cell lysates were subjected to
western blotting for Trx1/2 and Prx1/2. The results shown are representative of three independent experiments. (C) Trx1 and Prx2 mRNA
levels were determined by RT–PCR. (D) VSMCs were incubated in the absence or presence of 0.5 mmol/L TSA for 24 h, and mRNA levels of
various NADPH oxidase components were determined using RT–PCR.
Role of Trx1 in TSA-mediated vascular proliferation 245accumulation and the subsequent induction of vascular prolifer-
ation, as in the case in Prx deﬁciency.
15 This possibility was sup-
ported by the ﬁnding that, in common with Trx 1 inhibition, Prx
2 knockdown increased the proliferation of VSMCs. However,
we cannot exclude the possibility that the enhanced migration of
VSMCs observed in our experiments was mediated by a decreased
interaction of Trx1 with target proteins other than Prx2, as Prx 2
knockdown did not induce any signiﬁcant increase in
serum-induced migration.
Compounds that can inﬂuence ROS generation are currently
under study for their potential use in the treatment of various dis-
eases, including cancer. However, little has been reported regard-
ing the ability of HDAC inhibitors to regulate the generation of
ROS, especially in normal cells. In a study examining the effect of
HDAC inhibitors on leukaemia and myeloid cells, they were
shown to promote apoptosis through an ROS-regulated
process.
22,23 However, in the current study, we demonstrated a
conﬂicting role for ROS in TSA-induced vascular proliferation;
speciﬁcally, we found that exposure to TSA led to an increase in
ROS accumulation and that treatment with ROS scavengers
signiﬁcantly inhibited activation of Akt, which is important for pro-
liferation and migration of VSMCs. Given our ﬁnding that ROS
regulate Akt activation, we speculate that, as a target of ROS,
Akt is a molecular mediator for TSA-mediated vascular prolifer-
ation. This hypothesis is supported by the report of Nishida
et al.,
24 that Akt is an ROS-responsive serine/threonine kinase,
and by our ﬁnding that downregulation of Trx1 increases ROS
levels and augments serum or PDGF-mediated Akt activation
in VSMCs.
In our experiment, we could not distinguish which Akt isoform
made the major contribution to vascular proliferation on TSA
treatment. A previous report showed that the Akt3 isoform is
expressed in substantial amounts by aortic VSMCs and coronary
artery VSMCs.
25 That study also showed that exposure of
VSMCs to PDGF led to a signiﬁcant increase in Akt3 activity,
which was much higher than the activity of Akt1 and Akt2.
25 Con-
sequently, we speculate that the Akt3 isoform plays an important
role in the TSA-induced proliferation of VSMCs, although all three
Akt isoforms are capable of increasing their respective activity on
PDGF treatment.
Figure 4 Effect of Trx 1 knockdown on the activation of the NADPH oxidase component. (A) VSMCs were transfected with Trx1-speciﬁc
siRNA and cultured for 48 h, at which time the efﬁciency of transfection was determined by western blotting. (B) In Trx1 siRNA-transfected
cells, intracellular ROS levels were determined by staining with DCF-DA. P-values are indicated for statistically signiﬁcant differences (Student’s
t-test). (C) VSMCs transfected with Trx1-speciﬁc siRNA were incubated in the absence or presence of 5% serum for 4 h, and then the mRNA
levels of NADPH oxidase components were determined by RT–PCR. (D) VSMCs transfected with Trx1-speciﬁc siRNA were incubated in the
absence or presence of 5% serum for 4 h, and soluble cell lysates were subjected to immunoblot analysis for p47phox. (E) VSMCs were trans-
fected with Trx1 siRNA for 48 h, and the lysates were then immunoprecipitated with anti-p47 phox. Phorbol myristate acetate (PMA)-treated
cells were used as a positive control. The immunocomplex was subjected to immunoblotting with anti-phosphoserine or anti-p47 phox, as
indicated on the right.
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regulate Trx and arrest cell growth in transformed ﬁbroblast,
VA-13, and prostate cancer cells.
2,13 In concordance with these
reports, we found that TSA treatment enhanced TRAIL-induced
apoptosis in transformed HeLa cells via downregulation of Trx1
(see Supplementary material online, Figure S1A and B). We also
found that Trx1 inhibition by siRNA led to increased levels of
p38 and JNK phosphorylation in HeLa cells (data not shown),
suggesting that the TSA-induced death of tumour cells is regulated
through alterations in MAP kinase signalling that mediate cell death
and are positively regulated by ROS. Our ﬁndings are supported by
reports that antioxidants inhibit ROS-induced cell death and acti-
vation of p38 and JNK.
26,27 The observation described here regard-
ing tumour cells is consistent with previous reports that HDAC
Figure 5 The effect of Trx 1 and Prx 2 inhibition on VSMC growth and migration. (A) VSMCs transfected with Trx1 siRNA were treated with
PDGF for 24 h, and growth rates were determined using the MTT assay (Tukey post hoc test applied to signiﬁcant group effects in analysis of
variance, F3,61 ¼ 57.38, P , 0.001). (B) After 48 h of transfection with Trx1-speciﬁc siRNA, VSMCs were incubated with various concentrations
of serum for an additional 24 h, and growth rates were measured (Tukey post hoc test applied to signiﬁcant group effects in analysis of variance,
F5,18 ¼ 136.96, P , 0.001). (C and D) VSMCs transfected with Trx1-speciﬁc siRNA were incubated in the absence or presence of PDGF or 5%
serum for 48 h, and migration was determined using a migration assay. P-values are indicated for statistically signiﬁcant differences (Student’s
t-test). The vertical axis represents the number of cells that migrated into the wounded region. Stacked bars display the portion of migratory
cells classiﬁed by migration distance. (E and F) VSMCs transfected with Prx 2-speciﬁc siRNA were incubated with various concentrations of
serum for an additional 24 h, and growth rates were measured (Tukey post hoc test applied to signiﬁcant group effects in analysis of variance,
F5,24 ¼ 32.92, P , 0.001), and migration was determined using a migration assay. P-values are indicated for statistically signiﬁcant differences
(Student’s t-test).
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3,5 Although TSA
treatment induced a reduction in Trx1 expression in both HeLa
and VSMCs, the ﬁnal outcomes were opposite: proliferative in
VSMCs and pro-apoptotic in transformed HeLa cells. We believe
that the observation of these divergent effects of TSA or Trx1
knockdown is unique to our study. However, the reasons as to
why tumour and normal cells respond differently to the same
TSA treatment remain unclear. It is tempting to speculate that
tumour and normal cells have different ROS-regulated molecular
targets. This hypothesis is supported by our ﬁnding that treatment
with TSA or transfection with Trx1-speciﬁc siRNA increased the
activation of different molecules in tumour cells (p38 and JNK)
and normal cells (Akt). Taken together, these data suggest that
although TSA exposure can increase ROS levels through the
downregulation of Trx1 in both VSMCs and HeLa cells, the mech-
anisms of action in the two cell types may be distinct from one
another.
In addition, we showed that the TSA-induced increase in ROS
did not occur through altered expression of NADPH oxidase com-
ponents. Of the NOX proteins, NOX 4 was expressed most highly
in VSMCs. The expression of NOX 2 was also detected, but the
expression level was signiﬁcantly lower. As expected, TSA treat-
ment did not affect the expression of NOX 1 or NOX 4
(Figure 3D). Although p22 phox was also highly expressed in
VSMCs, its expression level was also not affected by TSA treat-
ment (Figure 3D). To further conﬁrm the involvement of Trx 1
on the expression of NADPH oxidase components, we examined
the effect of Trx 1 knockdown on the serum-induced expression
of NADPH oxidase components. Serum addition suppressed the
NOX 4 and p22 phox expression, and this suppressive effect did
not differ between cont siRNA- and Trx 1 siRNA-transfected
cells (Figure 4C). This effect is almost consistent with a previous
result that NOX 4 and p22 phox expression was affected by
serum mitogen.
28 The expression of p47 phox, the cytosolic com-
ponent of NADPH oxidase, was not changed by Trx 1 knockdown
(Figure 4D). These results suggest that Trx 1 knockdown does not
change the expression of membranous and cytosolic NADPH
oxidase components. We also showed that the phosphorylation
of p47 phox was not affected by Trx 1 knockdown (Figure 4E).
Given our ﬁndings, it is possible that the ROS accumulation on
TSA treatment or Trx1 knockdown is not due to the activation
of ROS-producing NADPH oxidase system, but to the downregu-
lation of the ROS-scavenging antioxidant system including Trx1
and Prx 2.
The mechanism by which TSA exposure leads to decreased
expression of antioxidant proteins remains to be elucidated.
Recent evidence has suggested several regulatory mechanisms con-
cerning the transcriptional or post-translational modiﬁcation by
HDAC inhibitors. HDACs generally act as components of large
co-repressor complexes that prevent gene transcription. Alterna-
tively, abundant evidence indicates that the reversible acetylation
of transcriptional regulators, such as TFIIEb, TFIIF, p53, NF-kB,
GATA1, and ELK, affects their DNA binding properties.
29 For
example, deacetylation of a lysine residue in the IkB protein, an
inhibitor of NF-kB, has been reported to promote its subsequent
ubiquitination and proteasome-dependent degradation.
30
Figure 6 Effect of Trx1 inhibition on Akt activation. (A and B) VSMCs were pre-incubated in the absence or presence of LY294002 for 1 h
and then treated with 5% serum for 24 h. Growth rates and migration activities were measured using MTT and migration assays (Tukey post hoc
test applied to signiﬁcant group effects in analysis of variance, F3,16 ¼ 88.72, P , 0.001 in MTT assay and F3,16 ¼ 179.31, P , 0.001 in migration
assay, *P , 0.001). The soluble cell lysates were subjected to western blotting. Results shown are representative of three independent exper-
iments. (C) VSMCs were pre-incubated in the absence or presence of 0.5 mmol/L Vitamin C or 25 mmol/L Mn-TBAP and then incubated with
serum for 15 min. The soluble cell lysates were subjected to western blotting. (D) VSMCs were transfected with Trx1-speciﬁc siRNA and
treated with 5% serum for 15 min or 48 h after overnight serum starvation. The soluble cell lysates were subjected to western blotting.
S. Song et al. 248Hyper-acetylation induced by HDAC inhibitors can therefore sup-
press the activation of NF-kB by stabilizing IkB. Because NF-kB has
been reported to regulate Trx transcription,
31 the inhibitory effect
of TSA on Trx1 may be mediated through NF-kB inactivation.
In conclusion, TSA enhances vascular proliferative activity by
downregulating Trx1 in an Akt-dependent manner. Because
various HDAC inhibitors have been tested and put to practical
use for cancer treatment, our results prompt the precaution that
HDAC inhibitors might have unexpected paradoxical
pro-atherogenic effects, especially in susceptible subjects with
high risk factors.
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